Publications by authors named "Maria Dolores Lopez-Lucas"
Background: The regenerative and immunomodulatory properties of human mesenchymal stromal cells (hMSCs) have raised great hope for their use in cell therapy. However, when intravenously infused, hMSCs fail to reach sites of tissue injury. Fucose addition in α(1,3)-linkage to terminal sialyllactosamines on CD44 creates the molecule known as hematopoietic cell E-/L-selectin ligand (HCELL), programming hMSC binding to E-selectin that is expressed on microvascular endothelial cells of bone marrow (BM), skin and at all sites of inflammation.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to create a decision tree to guide the biodistribution assessment of cell-based therapies, which is important for ensuring safety during preclinical development as current protocols are complex for developers and regulators.
- - Eight different studies using various animal models and methods (like PCR and MRI) were analyzed, focusing on the administration of mesenchymal stromal cells (MSCs) to understand their distribution and safety in both small and large animals.
- - The findings suggest that a standardized approach using different animal models and techniques can improve the accuracy, cost-effectiveness, and efficiency in evaluating the safety of these therapies, with PCR being favored despite some limitations.
Introduction: Therapeutic application of intravenous administered (IV) human bone marrow-derived mesenchymal stem cells (ahMSCs) appears to have as main drawback the massive retention of cells in the lung parenchyma, questioning the suitability of this via of administration. Intraarticular administration (IAR) could be considered as an alternative route for therapy in degenerative and traumatic joint lesions. Our work is outlined as a comparative study of biodistribution of Tc-ahMSCs after IV and IAR administration, via scintigraphic study in an animal model.
View Article and Find Full Text PDF